Discovery of new quaternized norharmane dimers as potential anti-MRSA agents
Discovery of new quaternized norharmane dimers as potential anti-MRSA agents
复制标题
DOI:
10.1016/j.jare.2023.11.005
复制
发表时间:
2024-08-18
影响因子:
10.7
通讯作者:
Wan,Jian-Bo
中科院分区:
文献类型:
--
作者:
Dai,Jiang-Kun;Dan,Wen-Jia;Wan,Jian-Bo
IntroductionMethicillin-resistantStaphylococcus aureus(MRSA)-caused infections greatly threaten public health. The discovery of natural-product-based anti-MRSA agents for treating infectious diseases has become one of the current research focuses.ObjectivesThis study aims to identify promising anti-MRSA agents with a clear mechanism based on natural norharmane modified by quaternization or dimerization.MethodsA total of 32 norharmane analogues were prepared and characterized. Their antibacterial activities and resistance development propensity were tested by the broth double-dilution method. Cell counting kit-8 and hemolysis experiments were used to assess their biosafety. The plasma stability, bactericidal mode, and biofilm disruption effects were examined by colony counting and crystal violet staining assays. Fluorescence microscopy, metabolomic analysis, docking simulation and spectra titration revealed its anti-MRSA mechanisms. The mouse skin infection model was used to investigate thein vivoefficacy.ResultsCompound5awas selected as a potential anti-MRSA agent, which exhibited potent anti-MRSA activityin vitroandin vivo, low cytotoxicity and hemolysis under an effective dose. Moreover, compound5ashowed good stability in 50% plasma, a low tendency of resistance development and capabilities to disrupt bacterial biofilms. The mechanism studies revealed that compound5acould inhibit the biosynthesis of bacteria cell walls, damage the membrane, disturb energy metabolism and amino acid metabolism pathways, and interfere with protein synthesis and nucleic acid function.ConclusionsThese results suggested that compound5ais a promising candidate for combating MRSA infections, providing valuable information for further exploiting a new generation of therapeutic antibiotics.